Conference Track

Pharmacology & Adverse Events

Source: CCO Independent Conference Coverage of the 2005 International AIDS Society Conference on HIV Pathogenesis and Treatment*

*CCO is an independent medical education company that provides state-of-the-art medical information to healthcare professionals through conference coverage and other educational programs.

Capsule Summaries

Lopinavir/Ritonavir-Based Regimen Produces Rapid Viral Load Decrease in Young Children Despite Low Plasma Drug Concentrations
Variable Plasma Drug Levels in Children Receiving Lopinavir/Ritonavir
HIV-1 Disease, Not HAART Use, Linked to Bone Demineralization
Elevated Incidence of Thyroid Disease Among Patients on HAART
Mitochondrial Toxicity Associated With Concurrent Tenofovir/Didanosine Treatment May Contribute to Renal Dysfunction
Significantly Increased Exposure to Coreceptor Antagonist Vicriviroc (SCH-417690) When Coadministered With Ritonavir
Ritonavir and/or Triple-NRTI Therapy Associated With Increased Risk of Renal Insufficiency in Tenofovir Recipients
Select Laboratory Adverse Events Related to Antiretroviral Therapy Predict Mortality
Novel Lopinavir/Ritonavir Formulation Decreases Variability in Drug Levels, Pill Burden
Adverse Effects Limit Usefulness of Combining Rifampin-Based Tuberculosis Regimens with Ritonavir/Saquinavir-Based Antiretroviral Therapy
Once-Daily Dosing of Lopinavir/Ritonavir Coformulation as Effective as Twice-Daily Dosing, But With Increased Diarrhea
No Observed Increase in Complications in South African Patients Initiating Nevirapine-Based HAART With Concomitant Rifampin

Expert Analysis

Pharmacology and Adverse Events

Program Director: John P. Phair, MD

Faculty:

Terrence F. Blaschke, MD
Courtney V. Fletcher, PharmD
William G. Powderly, MD

Learning Objectives

Upon completion of this activity, participants should be able to:

Describe recent data on drug-drug interactions between antiretroviral agents.
Review data on adverse effects associated with the use of Highly Active Antiretroviral Therapy (HAART).
Discuss novel dosing regimens for administration of lopinavir/ritonavir in adults and children.

CREDIT INFORMATION

Release Date: September 23, 2005

Expiration Date: September 22, 2006

Physicians: maximum of 1.25 AMA PRA Category 1 Credits™

Registered Nurses: 1.6 Nursing contact hours

Pharmacists: 1.4 contact hours (0.14 CEUs)

Status: The activity is not currently available for credit.

Disclaimer: The materials published on the Clinical Care Options Sites reflect the views of the reviewers or authors of the CCO material, not those of Clinical Care Options, LLC, the CME provider, or the companies providing educational grants. The materials may discuss uses and dosages for therapeutic products that have not been approved by the United States Food and Drug Administration. A qualified healthcare professional should be consulted before using any therapeutic product discussed. Readers should verify all information and data before treating patients or using any therapies described in these materials.